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 Chapter 11 
 Neurological Diseases from a Systems 
Medicine Point of View 
 Marek  Ostaszewski ,  Alexander  Skupin , and  Rudi  Balling 
 Abstract 
 The diffi culty to understand, diagnose, and treat neurological disorders stems from the great complexity 
of the central nervous system on different levels of physiological granularity. The individual components, 
their interactions, and dynamics involved in brain development and function can be represented as molecular, 
cellular, or functional networks, where diseases are perturbations of networks. These networks can become 
a useful research tool in investigating neurological disorders if they are properly tailored to refl ect corre-
sponding mechanisms. Here, we review approaches to construct networks specifi c for neurological disor-
ders describing disease-related pathology on different scales: the molecular, cellular, and brain level. 
We also briefl y discuss cross-scale network analysis as a necessary integrator of these scales. 
 Key words  Systems medicine ,  Multiscale brain networks ,  Network reconstruction ,  Molecular networks , 
 Cellular networks ,  Connectome ,  Cross-scale analysis ,  Neurodegenerative diseases ,  Epilepsies 
1  Introduction 
 The human brain is an organ of an extraordinary complexity, where 
high-level processes emerge from simultaneous and continuous 
interaction of mechanisms on molecular, cellular, and anatomical 
scales. We need to properly analyze this complexity to be able to 
address the question of how brain disorders should be diagnosed 
and treated. A systems approach is a proper paradigm to address 
 the challenges of brain pathophysiology. 
 The dynamics and close coupling between different scales of 
brain physiology are already clearly seen in the development of the 
nervous system. Importantly, the molecular and cellular processes 
observed in acute and chronic diseases often refl ect and reuse 
mechanisms  of embryogenesis. Many of the canonical pathways 
such as sonic hedgehog, Wnt, FGF, BMP, and their underlying 
 If you look at the anatomy, the structure, the function, there's nothing in the universe that’s more beautiful, 
that’s more complex, than the human brain. Keith Black 
222
transcriptional regulatory networks are highly conserved during 
evolution. The homologs or paralogs of certain genes are expressed 
at different times and in different pre- and postnatal cell lineages 
[ 1 ]. For instance, genes required in the formation of the embry-
onic vascular system are re-expressed during wound healing in 
adults. Of course the context of these evolutionary conserved 
modules within the circuitry of the adult organism differs greatly, 
which might lead to a different outcome after activation of their 
expression in an embryonic versus an adult environment [ 2 ,  3 ]. 
Nevertheless developmental biology can very well inform and sup-
port the generation of hypotheses about the disease pathogenesis, 
especially considering that the developmental processes integrate 
control on molecular, cellular, and anatomical levels, and the 
perturbation of this control may refl ect the pathogenesis on the 
later stages [ 4 ,  5 ]. 
 One of the earliest events during embryogenesis is the determina-
tion of the principal body axis. Following the development of the 
primitive streak and the formation of the notochord, different cell 
layers, mesoderm, ectoderm, and endoderm are formed. The ecto-
derm located immediately dorsally to the notochord is induced to 
form neuroectoderm, the precursor of the nervous system. The 
 neuroectoderm , initially a fl at sheet, then folds into the neural tube, 
which in itself differentiates further into a number of neuronal dif-
ferent cell types dependent on their anterior-posterior, dorsal- 
ventral, and lateral position [ 6 ]. The development of the specifi c 
neuronal cell types within the spinal cord and the brain including 
the formation of the peripheral motor and sensory system can be 
traced back to the induction and programming during these specifi c 
early developmental phases [ 7 ]. 
 The most anterior part of the neuroectoderm and the neural 
tube develop into the brain as a result of highly complex folding, 
proliferation, and migration events [ 8 ]. In this period the segmen-
tal nature of the brain becomes masked by region-specifi c migra-
tion and outgrowth of specifi c brain regions, for instance the 
cortex. Newly developing neurons contain cell-autonomous posi-
tional identity information and in addition receive spatial intracel-
lular and extracellular cues guiding their migration and homing 
within the developing embryo in an anterior-posterior as well as a 
dorsal-ventral direction. These events are overlaid by the expres-
sion and activity of intricate cell survival, apoptotic, proliferation, 
and differentiation signals, leading to the fi nal formation of the 
different  neuronal and glial cell types and their wiring into the fi nal 
connectome of the brain [ 9 ]. Already during embryogenesis 
electrical activity of neurons starts and is an  important factor in the 
development of the nervous system [ 10 ]. 
 Similarly to neural tube formation, specifi c molecular and 
cellular processes govern the segmentation into specifi c 
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components of nervous system. One of them is the formation of 
the midbrain- hindbrain boundary, refl ecting the pronounced 
segmentation of the developing brain [ 11 ]. One of the key path-
ways driving this process is  the Wnt pathway. A series of hierarchi-
cally organized transcription factors (e.g., EN1, PAX2, PAX8) and 
secreted morphogens (WNT1, SHH, FGF8) set up an asymmetry 
at a precise anterior-posterior boundary [ 12 ]. It is at this interface 
where an “organizing center” forms, leading to the differentiation 
and outgrowth of various neuronal precursors, for instance of the 
dopaminergic neurons. Tracing specifi c neuronal subtypes and 
assigning them specifi c gene expression signatures have greatly 
facilitated our understanding of the underlying wiring principles of 
the nervous system. 
 Brain development is a process integrating different layers of 
biological complexity, from genetic programs and molecular mech-
anisms, through cellular interactions and migration, to the devel-
opment of functional anatomical regions. It is expected that 
perturbation of these networks may result in pathogenic states of 
the brain. Indeed, recent fi ndings suggest that molecular, cellular, 
and anatomical  dysfunction  during brain development are for 
example resulting in epilepsies [ 13 ]. Interestingly components of 
the Wnt pathway are affected in diseases associated with the spe-
cifi c brain regions or neurons later on [ 14 ,  15 ]. These fi ndings fuel 
intensive efforts under way to develop systems-based computa-
tional models for many of the molecular events of nervous system 
development. 
 The integration of mechanisms on different layers takes place 
across the whole life-span of the brain, through its homeostasis to 
degeneration. Similarly, it is needed to integrate spatial and tempo-
ral scales of representation of brain disease to be able to grasp the 
full picture of neuropathogenesis. 
 The processes of brain  development , homeostasis and function, 
and neurodegeneration are complex. Elaborated architecture and 
functionality on molecular, tissue, and anatomical levels are con-
stantly changing due to intrinsic brain functions and interactions 
with the environment. Disorders of such a complex system affect 
different aspects of its function, ranging from molecular structure, 
through dysfunction of neuronal subpopulations, to alteration of 
anatomical or functional brain connectivity. To be able to properly 
address the challenge of neurological disorders, we need to under-
stand key processes implicated in brain function. For this purpose, 
existing knowledge is being combined with experimental readouts 
to construct networks describing pathological processes on 
 molecular, cellular, and anatomical levels in the brain. Constantly 
improving analytical methods are applied to dissect structure and 
dynamics of these networks in an attempt to understand the 
pathology behind. 
1.2  A Systems 
Approach is Required 
for Neurological 
Disorders
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 However, this systems  approach is not suffi cient to fully answer 
challenges of neurological disorders. The networks of dynamic 
topology, responsible for emergence of coherent function of the 
brain, should be considered along with their relation to other scales 
of brain organization. For instance, frequency and amplitude of 
neuronal fi ring that maps onto interactions of neurons and other 
cells should be considered in the context of the function of 
anatomical location containing the neurons, as well as molecular 
processes responsible for the fi ring. 
 In the following sections we review the three physiological 
scales to consider when approaching neurological disorders: 
molecular, cellular, and the whole brain. We discuss recent 
approaches to characterize components of networks on these 
scales, and to construct and refi ne networks specifi c to each scale. 
Finally, we emphasize the need for cross-scale network analysis to 
gain further understanding of the complexity of neurological 
disorders. 
2  Molecular Interaction Networks 
 Characterization of disease-related mechanisms on the level of 
molecular neurobiology is both necessary and extremely challeng-
ing.  Our knowledge of the physiology of neuronal and glial cells is 
still limited, mostly because the brain tissue is both heterogeneous 
and diffi cult to access. In effect, molecular networks usually repre-
sent only a reduced view of the molecular biology of nervous cells. 
Figure  1 illustrates this reduced network view next to a cell it 
represents.
 This reduced, but not reductionist, view is the essence of 
disease- oriented molecular networks. The network has to model 
the processes implicated in the pathogenesis; thus it has to focus 
only on relevant components and interactions. However, taking 
into account the multitude of processes implicated in neurological 
disorders, identifying which elements of the molecular networks 
are relevant is not a trivial task [ 16 ]. 
 Typical components and corresponding interaction types of 
molecular networks are  listed  in Table  1 , with an indication of 
 potential interactions between different components. It should be 
emphasized that the network representation describes dynamical 
processes and the abovementioned interaction types have various 
temporal and spatial resolutions. For instance, the axonal transport 
of substrates of synaptic activity is quite different from the calcium 
transport across the neuronal membrane.
 The focus of disease-specifi c molecular networks depends on the 
nature of the pathogenesis. This scope ranges from well-defi ned 
mechanisms through a set of implicated pathways to a number of 
2.1  Components
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involved molecules. The focus of the molecular network is in effect 
closely related to questions that systems-level analyses should 
answer. The more focused the network model, the more precise 
Nucleus
 Fig. 1  A network representing molecular processes in a neuronal cell, illustrating the reduced network view of 
complex cell physiology.  Activation and  inhibition  interactions describe regulatory events within a neuronal 
cell.  Catalysis interaction denotes a catalyst role of an element. Conversion refers to change of state of mole-
cules, be it biochemical reaction, or protein complex assembly. Transport describes translocation of molecules 
within the neuronal cell, or across its boundaries 
 Table 1 
 Elements and interaction types typically used for constructing molecular 
networks.  See Fig.  1 for description of interaction types 
 Interaction types 
 Element types  Regulatory  Catalytic  Conversion  Transport 
 Gene/mRNA  •  • 
 MicroRNA  • 
 Protein  •  •  •  • 
 Small molecule  •  •  • 
 Pathway  •  •  •  • 
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questions may be asked, up to the level of high-quality, computable 
metabolic models [ 17 ]. 
 In the case of prion-like diseases, the causative mechanism is a 
misfolding prion protein, inducing neurodegeneration and spread-
ing across the nervous system [ 18 ]. Regardless of our insight into 
the structural properties of prions [ 19 ], the knowledge about the 
pathology of this single molecular mechanism is insuffi cient to pro-
pose a cure. 
 Huntington’s disease (HD) is a genetic  disorder  caused by 
excessive glutamine repeats in the gene encoding the huntingtin 
protein [ 20 ]. Such mutated huntingtin induces formation of 
pathogenic inclusions in neuronal cells and is supposed to burden 
their protein degradation systems. Although the genetic factor is 
convincingly identifi ed, the exact mechanism of molecular neuro-
pathology remains elusive. 
 Chronic  neurodegenerative disorders , like Alzheimer’s disease 
(AD) or Parkinson’s disease (PD), are infl uenced by a combination 
 of  genetic and environmental factors [ 21 ,  22 ]. A number of famil-
ial genes and disease-inducing toxins indicate a range of molecular 
pathways affected in the course of these diseases. Nevertheless, 
causative factors remain unclear. 
 Epilepsies are neurological disorders where genetic compo-
nents are known, or become a risk factor. Here, dysfunction of 
molecular mechanisms leads to the emergence of pathology on 
higher levels of organization of the central nervous system [ 23 , 
 24 ]. The utility of molecular networks in studying this class of dis-
order seems to be limited, as existing approaches are reductionistic, 
not able to apprehend the complexity of the pathology [ 25 ]. 
 Construction of networks refl ecting molecular level of neuropa-
thology usually follows a number of well-defi ned steps. In general, 
these are (a) identifi cation of candidate molecules, (b) connection 
of the molecules by querying databases or manually curating the 
interactions, and (c) refi nement and evaluation of the network. 
 Identification  of candidate molecules to construct a molecular net-
work is often supported by high-throughput screens in experimen-
tal disease models. In many cases associative networks are 
established using the underlying data, i.e., networks, where inter-
actions do not represent any mechanistic link between connected 
elements. In the end, these associative networks support candidate 
prioritization for assembling disease-related, mechanistic models 
[ 26 – 28 ]. 
 For prion diseases, mouse models [ 29 ], cellular models [ 30 ], 
and yeast genetic screens [ 31 ] supported construction of molecu-
lar networks. Similarly for HD-related pathology, yeast screens 
helped to  prioritize candidates for network construction [ 32 ]. 
Whenever available, human  postmortem tissue is used for omics 
2.3  Construction 
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profi ling allowing, for instance, to pinpoint genes involved in PD 
[ 33 – 35 ] and AD [ 36 ,  37 ] pathogenesis. Interestingly, candidates 
for molecular interaction networks in case of certain epilepsies base 
on reconstruction from brain tissue biopsies collected during sur-
gical procedures [ 38 ]. 
 Establishing interactions  between  candidate molecules can involve 
querying databases of molecular mechanisms [ 39 ], or manual 
curation [ 40 ]. Profi ling of the transcriptome combined with 
literature- based  network reconstruction has  been proposed for 
instance for prion diseases [ 29 ,  41 ] or AD [ 42 ] as a method to 
indicate pathways affected during the disease progression. Network 
reconstruction based on genomic data, i.e., focused on genetic risk 
factors of neurological diseases, was proposed for prion [ 43 ], epi-
lepsies [ 44 ], and PD [ 45 ]. 
 The construction of molecular networks may require manual 
curation either to de novo assemble the interactions between can-
didate molecules or to review an automatically constructed net-
work. Development of a large-scale, disease-focused network is a 
challenging task. In the fi elds of AD [ 46 ] and PD [ 47 ], heteroge-
neous molecular interaction maps were established. A more focused 
approach resulted in the curation of existing metabolic pathways 
into a brain-specifi c network [ 40 ]. Finally, in the fi eld of PD, even 
more focused network-based models were constructed, represent-
ing in detail processes related to cellular stress of neuronal metabo-
lism and to protein misfolding [ 48 ,  49 ]. 
 Networks constructed on the  basis of analytically identifi ed candi-
date molecules and interactions are prone to bias. Evaluation and 
refi nement of constructed networks should be performed to ensure 
their proper focus. The quality of established disease-related net-
works may be evaluated using relevant experimental datasets 
mapped on the network structure. Fujita et al. proposed to visual-
ize brain tissue transcriptomics data on their manually curated 
PD-relevant network [ 47 ], what allows to assess its relevance. In 
case of epilepsies such an evaluation helps to tailor networks for 
different disease subtypes, for instance focusing on specifi c neuro-
nal receptors [ 50 ] or fi ltering using gene expression profi les from 
brain tissue of pharmacoresistant cases [ 51 ]. In addition to human 
brain samples, datasets from disease-related experimental models 
can be similarly applied [ 52 ,  53 ]. Especially experimental setups 
focused on detailed analysis of specifi c pathways are useful in such 
a network evaluation. For instance, recent work on the mecha-
nisms of the Wnt signaling pathway [ 54 ] produced time series of 
gene expression  following  Wnt stimulation. Network analysis of 
these series confi rmed known mechanisms governing canonical 
and noncanonical activation of the Wnt-pathway, and shed light on 
molecular mechanisms relevant for AD. Although the constructed 
2.3.2  Connection 
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network was associative, such gene expression time series data can 
also be mapped on curated, mechanistic models of the disease to 
validate their accuracy in refl ecting crucial mechanisms. 
 Besides using tissue-specifi c experimental datasets, additional 
sources of information can be applied to refi ne the shape of devel-
oped molecular networks. Recently, microRNAs gained attention 
as potential modulators of neurological disorders [ 55 – 57 ]. These 
regulators of mRNA are especially relevant when constructing 
brain-focused, gene regulatory networks. Similarly, DNA methyla-
tion, or protein acetylation, emerges as a potent regulator of a large 
number of genes in neurological disorders [ 58 – 60 ], which can 
affect entire functional modules of molecular networks. 
 Molecular networks of brain disorders are very heterogeneous, 
such as the data sources used for their construction. Molecular 
mechanisms of the brain are studied using experimental models, 
postmortem tissue, and, in particular cases, brain biopsies. When 
constructing these networks, a trade-off has to be made between 
network breadth and depth. Large-scale networks provide an over-
view of disease processes, allowing limited analytical approaches 
[ 47 ]. Moreover, they enable studies on molecular cross-disease 
comparison, aiming to elucidate overlapping mechanisms between 
diseases like AD or PD, and diabetes or autoimmune diseases [ 61 –
 63 ]. In turn small, focused networks can describe disease-related 
processes with high quality and using established mathematical 
frameworks. Simulation of dynamics in such networks allows pre-
dictions on causality and temporal resolution of represented pro-
cesses [ 48 ,  64 ]. 
 Importantly, molecular networks should not be considered as 
stand-alone structures. The cellular machinery of brain cells works 
in the context of its embedding tissue, which in turn forms func-
tional areas of the brain. Thus, although prion pathology has a 
molecular basis, the disease has to be considered also from the 
perspective of higher order networks. Recent fi ndings on prion 
interactions with GABA receptors and their infl uence on excito-
toxicity allow forming a link  with cellular networks [ 65 ]. This link 
is further reinforced by the fi ndings on the modulatory role of 
prion protein in the dopaminergic system [ 66 ]. It might be 
 necessary to bridge molecular and brain layers to explain symptom-
atic biomarkers of prion disease [ 67 ]. 
 Our knowledge on the molecular basis of HD is insuffi cient to 
explain its pathogenesis. This fact suggests broadening the scope of 
systems analysis beyond the molecular interaction networks. Studies 
correlating genetics of early HD with neuroimaging studies form a 
bridge between molecular and brain-level networks [ 68 ]. 
 Importantly, higher levels of network representation should be 
considered when analyzing molecular mechanisms. In PD, degen-
eration of a particular neuronal populations is observed, 
2.4  Summary: 
Molecular Networks
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suggesting that cellular interactions [ 69 ,  70 ] play an important 
role in the pathology. Moreover, growing body of evidence points 
towards pathological spreading of synuclein aggregates across 
brain areas [ 71 ,  72 ] as the key mechanism of PD. Higher levels of 
network organization may provide further understanding in PD 
pathology. Recent studies in AD and PD follow this concept by 
analyzing omics of different brain areas affected in PD and AD 
[ 37 ,  73 ], or genetic factors affecting functioning of brain-level 
networks [ 74 ,  75 ]. 
 The molecular  pathogenesis of epilepsies contributes signifi -
cantly to the pathology of networks of higher order [ 76 ]. Therefore, 
the need for systems biology is pressing, as their emergent proper-
ties span not only over many elements of molecular networks, but 
also over different network layers. 
3  Cellular Interaction Networks 
 The human  brain  consists of approximately 10 9 neurons, each of 
which has on average 100,000 synaptic connections to other neu-
ronal cells [ 77 ,  78 ]. This plethora  of  neuronal interactions reveals a 
well-defi ned network structure, established already during the 
developmental stage. This network has varying spatiotemporal 
characteristics as some cells are more locally connected whereas 
others project to distant regions within the brain and the body, with 
some connections being longer than a meter [ 79 ,  80 ]. Moreover, 
the interaction modes between neuronal cells are diverse, being 
either excitatory or inhibitory in dependence on neurotransmitters 
and corresponding receptors of their synapses. 
 While the main brain structure remains stable over lifetime, the 
brain demonstrates a huge local plasticity compared to all other 
organs, enabling learning and memory.  This plasticity is achieved 
by an input-dependent rewiring of the neuronal network topology 
in specifi c brain regions like the hippocampus and the cortex. 
The main mechanisms for this rewiring are long-term potentiation 
and long-term depression that alter synaptic connection between 
neurons in an activity-dependent manner according to Hebb’s 
learning rule [ 81 ,  82 ]. 
 Importantly, the human brain consists of more than 50 % of 
glial cells that play an important role in the activity of brain cellular 
networks. Among these cells astrocytes are the majority, comple-
mented by oligodendrocytes and microglia [ 83 ].  Astrocytes trans-
late neuronal activity and the related energy demands to blood 
fl ow regulation and corresponding uptake of glucose and oxygen 
to facilitate neuronal metabolism [ 84 ,  85 ].  Oligodendrocytes 
 insulate axons of the neurons by myelin sheets that allows for fast 
signal transduction and protects the fragile structure from the 
exterior [ 86 ]. Microglia represent the  macrophages  of the brain. 
3.1  Components
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They sense pathogens and damaged cells, migrate to the specifi c 
areas, and clean them by phagocytosis [ 87 ]. Figure  2 gives a sche-
matic overview of  these  interactions including a corresponding 
network representation.
 The brain exhibits a wide and heterogeneous spectrum of cel-
lular interactions that covers many spatial and temporal scales. The 
fastest intercellular signaling occurs between neurons on a millisec-
ond time scale [ 88 ]. Thereby electric impulses of axon potentials 
are transmitted at synapses to connected cells. This fast communi-
cation and typical feedback loops enable fast perception, appropri-
ate responses, and refi nements of actions [ 89 ]. Importantly, the 
signaling within the neuronal network is also infl uencing the sur-
rounding glia, which in turn can modulate the neuronal 
communication. 
 Astrocytes seal up the synaptic cleft to facilitate chemical 
information transmission and are responsible for clearing the neu-
rotransmitters from the cleft and recycling them back to the pre-
synaptic terminal [ 90 ]. Importantly, astrocytes express receptors 
for diverse neurotransmitters. For instance, the glutamate release at 
 Fig. 2  The diverse  cell  types within the brain generate a complex interaction network with different classes of 
interaction edges that also exhibit distinguished dynamic properties. Excitable connections (excitatory or 
inhibitory) denote action potentials of the neurons. Metabolic and trophic support interactions represent 
exchange of substrates required for cellular network homeostasis. Topology-altering interactions denote cel-
lular mechanisms leading to changes in the local network structure 
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glutamatergic synapses activates not only the postsynaptic neuron 
but also the surrounding astrocytes. Activated astrocytes increase 
their cytosolic Ca 2+ on the time scale of seconds, which triggers 
downstream signaling processes including potential release of ATP 
and glutamate [ 91 ]. This release induces the regulation of the 
blood fl ow but also a local amplifi cation process [ 92 ]. Subsequently, 
the signal can propagate within the astrocytic network by inter-
cellular Ca 2+ waves activating tens of cells and spreading hundreds 
of micrometer [ 93 ], where it may induce or modulate neuronal 
activity including synapse genesis by long-term potentiation and 
long-term depression [ 94 ]. 
 Oligodendrocytes support neuronal functionality by myelina-
tion that occurs on the time scale of minutes to hours [ 87 ]. 
Moreover, recent fi ndings point to their role in metabolic support-
ing and regulation of neuronal function [ 95 ,  96 ]. Similarly, microg-
lia have a long-term infl uence on neuronal dynamics. Besides 
removing pathogens and cell debris, including damaged neurons 
from the brain,  microglia  are responsible for synapse pruning [ 97 ]. 
The resulting changes in the neuronal network topology occur on 
the time scale of hours and are essential for brain function. 
Interestingly, a similar role was recently reported for astrocytes 
[ 98 ]. Table  2 gives an overview on the different cell types and their 
role in brain dynamics.
 Overall, the huge neuronal connectivity of neurons leads to 
dense network structures that translate the nonlinear dynamics of 
the single entities into a mesoscopically more ordered behavior. 
The resulting fi ne-tuned activity patterns often exhibit locally syn-
chronized fi ring of neurons that correspond to specifi c representa-
tions of information such as visual memory [ 99 ] or movement 
controls [ 100 ]. The underlying neuronal microcircuits are embed-
ded in and modulated by a number of regulatory cellular interac-
tions that allow for their plasticity and adaptation by changing the 
network topology [ 89 ]. To integrate the different involved levels 
and scales, we need to rely on systems approaches. 
 Table 2 
 Elements  and  interaction types of cellular networks. The temporal 
resolution of each interaction is explicitly indicated 
 Interaction types 
 Element types  Excitable  Metabolic  Topology altering 
 Neuron  Milliseconds  Seconds  Hours 
 Astrocyte  Seconds  Seconds/minutes  Hours 
 Oligodendrocyte  Minutes/hours 
 Microglia  Minutes  Hours 
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 The challenge to identify disease-specifi c network topologies and 
dynamics is to distinguish between primary and secondary effects. 
Within this context, the general question arises as to how single- 
cell properties refl ecting individual entities are translated to the 
cellular network behavior that may cause the pathology. 
 A direct link between molecular modifi cation and impaired 
network dynamics  is  observed in epilepsy. In this case, a single 
mutation of a channel protein can lead to increased excitability on 
a single-cell level, inducing more frequent spiking [ 101 ,  102 ]. 
Nodes with such modifi ed properties within the cellular network 
can induce drastic changes in the mesoscopic dynamics. Higher 
excitability of single cells can cause globally synchronized activity 
of many neurons, inducing seizures. At the same time, the affected 
cellular network is often capable to compensate for synchronized 
fi ring. In effect, both time and brain area of seizure occurrence are 
diffi cult to predict [ 103 ]. Interestingly, for cases where antiepilep-
tic medication does not exhibit seizure-suppressing effects, a pos-
sible therapy is to remove parts of the temporal lobe or to disconnect 
specifi c projections that allow for seizure spreading [ 104 ]. 
 In case of HD, the pathogenic genetic factor is well correlated 
with the cellular phenotype. Resulting neurodegeneration pre-
dominantly takes place in the striatum; however the mechanistic 
relation between the single-cell characteristic and the pathogenesis 
on the cellular network level is still not understood. Recent reports 
suggest an increased neuronal activity that induces larger energy 
demands and facilitates aging in the corresponding brain areas, 
leading to earlier cell death [ 105 ]. 
 Similarly, current evidence on PD points to an unbalanced 
energy budget of dopaminergic neurons in the substantia nigra and 
their corresponding intercellular interactions [ 106 ,  107 ]. Selective 
vulnerability of these neurons comes from their extra energy demand 
due to dopamine synthesis and homeostasis of long projections. 
Disturbances in the energy balance prime these neurons for an early 
cell death [ 108 ]. Moreover, the proportion of glia, and their result-
ing metabolic support, within affected regions of  dopamine synthesis 
is lower compared to other brain areas [ 109 ]. Another factor of 
dopaminergic degeneration may be the intracellular spreading of 
misfolded α-synuclein protein [ 110 ,  111 ]. In consequence to the 
tissue-level stress excessive degeneration of dopaminergic neurons in 
the substantia nigra depletes the pool of striatal dopamine, affecting 
the basal ganglia feedback loop coordinating signals from the periph-
eral nervous system and the sensomotoric cortex [ 112 ]. 
Consequently, thalamic neurons fi re synchronously, inducing the 
stereotypic tremor. The activity of  these  neurons can be targeted by 
deep brain stimulation ( DBS) that de-synchronizes the neuronal 
activity and suppresses the tremor [ 113 ]. 
 The  molecular basis of deregulation of cellular networks can be 
observed in prion diseases. The misfolding chain reaction  leads to 
3.2  Disease-Specifi c 
Network Topology
Marek Ostaszewski et al.
233
intra- or extracellular aggregates and eventually to neuronal death 
[ 114 ]. The associated changes of the neuronal network structure 
and corresponding dynamics subsequently evoke neurological 
symptoms such as dementia. Compared with the described direct 
dynamical impairments in epilepsy or PD that are observable by 
highly synchronized neuronal activity, the consequences of the 
modifi ed network topology in most prion diseases are less under-
stood [ 115 ]. A promising approach for a unifying perspective on 
neurodegeneration is brain energy metabolism linking many phe-
notypic traits and symptoms across several diseases [ 116 ,  117 ]. 
 Cellular networks are diffi cult to  construct due to the huge struc-
tural and dynamical complexity of represented interactions, in par-
ticular the specialized neuronal morphology and the extraordinary 
synaptic connectivity of the neuronal network. The architecture of 
glial cells, although less elaborate than of neurons, also features 
processes and multicellular interactions. Determination of a cellu-
lar network topology from such a heterogeneous and intercon-
nected mosaic of cells is a nontrivial task for neurohistology. 
 A fi rst approach to this problem, proposed by Golgi, was the 
low-effi ciency plasma membrane staining with silver chromate. 
The resulting single-neuron stains revealed the ramifi ed morphol-
ogy of neurons and the layer-like organization of the cortex [ 118 ]. 
However, this approach is not suited for identifi cation of cellular 
networks, as only a subset of cells is labeled in a region of 
interest. 
 Currently, electron microscopy is applied to track the neuronal 
interconnections, down to their fi ne substructures [ 119 ,  120 ]. 
The resulting large data sets have to be subsequently analyzed, 
mainly manually, because the variety of synaptic topologies limits 
automated segmentation approaches. More recent developments 
of synapse-specifi c dyes [ 121 ] enable  more high-throughput inves-
tigations and functional regulation studies [ 122 ,  123 ]. A general 
limitation of all these approaches is that they can identify individual 
synapses but are unable to allocate these to specifi c neuron-neuron 
connections. In  the  context of network reconstruction, this means 
that only the edges of the neuronal network are identifi ed without 
the necessary node associations. 
 This intrinsic diffi culty of studying cellular networks in human 
brain tissue brought a signifi cant focus to animal model studies. In 
2007, Lichtman and coworkers established a landmark invention 
addressing the neuronal connectivity challenge with their trans-
genic Brainbow mouse model. The approach is based on the ran-
dom expression of fl uorescent proteins of different colors [ 124 ] 
producing cell-specifi c color mixtures that enable to discern single 
neurons and identify their connections. In effect,  it became possi-
ble to describe whole neuronal microcircuits [ 125 ]. Although the 
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 Brainbow method allows for identifi cation of neuronal connections, 
it provides no information on network dynamics. 
 In the cellular networks of the brain, dynamics is of crucial 
importance with respect to synaptic signaling and plasticity. 
Moreover, interactions between glia and neuron-glia cross talk 
cannot be inferred from histological information as they take place 
in the extracellular space without direct cell-to-cell connections 
[ 126 ]. Currently, the dynamics of the cellular networks [ 127 – 129 ] 
are studied using in vitro approaches [ 130 ], which provide a good 
footing to understand disease-specifi c modulation of network 
dynamics in vivo [ 131 ]. Recent developments combining genetics 
and optics enable well-controllable optogenetic experimental 
model systems for neuronal microcircuits [ 132 ,  133 ]. Application 
of two-photon microscopy on a brain with genetically modifi ed 
reporters allows imaging of brain areas and optical control of neu-
ronal activity [ 134 ]. Imaging and control of neuronal microcir-
cuits are especially plausible to study disorders featuring acute 
neuronal misfi ring, like epilepsy. For other neurological diseases, 
with a chronic impairment of neuronal network dynamics and 
associated topology, cellular network reconstruction requires more 
input information concerning in particular the  modulatory effect of 
neuron-glia interactions [ 135 ,  136 ]. However, establishing these 
interactions in the cellular networks will require approaches allowing 
simultaneous molecular and activity profi ling. 
 The original  Brainbow method is restricted to optically accessible 
regions. As two-photon microscopy allows for penetration of tis-
sues to the range of a few mm [ 137 ], this approach is still beyond 
typical mammalian brain size. To overcome these limitations, new 
methods have been developed, allowing to remove the lipids of the 
tissue by electrophoresis, leading to transparent organs [ 138 ,  139 ]. 
Clearing a brain and applying specifi c fl uorescent antibody staining 
enable imaging of a whole brain on single-cell resolution without 
any sectioning. The resulting brain maps do not only include all 
neuronal connections [ 9 ] but can also provide spatial information 
on glia localization. When imaging such a treated brain of a patient 
with autism, Deisseroth and colleagues found abnormal neuronal 
projections that exhibit closed loops within individual cells [ 138 ]. 
This fi nding demonstrates how a modifi ed structure may infl uence 
brain dynamics and behavior. 
 Despite the substantial progress, the clearing methods are still 
restricted to the analysis of a fi xed tissue and are unable to monitor 
the intricate interplay of neuronal network dynamics and structural 
development. This challenge may be addressed in near future in 
zebrafi sh experiments [ 140 ]. The transparency of the fi sh and the 
availability of genetically encoded Ca 2+ dyes combined with appro-
priate image analysis tools [ 141 ] will allow for system-wide data 
acquisition that has to be inferred with computational modeling 
3.3.3  Refi nement 
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[ 129 ] for a mechanistic understanding of brain dynamics. Another 
strategy is to optimize noninvasive diffusion MRI and fMRI tech-
niques ( see Subheading  4 ) to single-cell resolution that could reveal 
microcircuit dynamics in patients and provide bottom-up under-
standing in neurological pathogenesis. The ambitious Human 
Brain Project [ 142 ] may become an integrative initiative for these 
approaches. 
 The evaluation of constructed cellular networks is possible 
in vivo with available methods. The optogenetics approach allowed 
Tønnesen and colleagues to achieve light-induced hyperpolariza-
tion of neurons in an animal model of epilepsy. Hyperpolarization 
of certain neuronal populations was found to suppress neuronal 
bursting, demonstrating new targets for epilepsy treatments [ 143 ]. 
In human brain, the technique of magnetoencephalography ( MEG) 
allows  to measure oscillatory activity of neuronal populations in 
given brain areas [ 144 ]. Although MEG lacks single-cell resolution, 
it allows to track disease-specifi c frequency patterns, which in turn 
may validate analytical outcomes of cellular network analyses. 
 The cellular network level bridges between molecular pathogenesis 
and the resulting neurological phenotype of the brain. The diver-
sity of the intercellular interactions and their  rich spatiotemporal 
spectrum ( see Table  2 ) render this level exceptionally complex to 
model. At the same time, cellular network analysis may indicate 
promising candidates for therapeutic interventions, as pathogenic 
cell properties may be altered by drugs targeting key molecular 
pathways, or corrected by tissue-level interventions like DBS. 
 The major challenge for a mechanistic understanding of these 
intercellular interactions is the high connectivity of the neuronal 
network and dynamics covering many spatiotemporal scales. This 
complexity permits experimental methods to focus only on a sub-
set of phenomena and integrative systems approaches are needed 
to understand underlying signaling mechanisms and support devel-
opment of novel therapeutic strategies. 
4  Brain-Level Networks 
 Network representation is very appropriate to describe brain-level 
activity. Connectivity of different anatomical and functional brain 
areas suggests effi cient network structure, optimized to provide 
high-level cognitive functions at a relatively low cost [ 145 ]. 
Disruption of this network is associated with pathological states of 
the brain. On the other hand, changes in the brain wiring may hap-
pen also due to compensatory mechanisms [ 146 ]. Similarly to net-
work representations on other levels, we face certain simplifi cation 
of extremely complex structure of the brain to a set of  elements 
and interactions. Figure  3 illustrates this situation.
3.4  Summary: 
Cellular Networks
4.1  Components
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 The number of components of such a network is quite limited, 
mostly due to the narrow scope of current neuroimaging 
approaches. In general, it is possible to measure functional areas of 
the brain by assessing oxygen consumption (fMRI-BOLD), or 
measure distribution of radiolabeled tracers (PET and SPECT). In 
turn, structural measurements are achieved assessing diffusion 
rates in asymmetric neuronal cells (DTI-MRI, or dMRI). Finally, 
our knowledge on brain topology provides us with certain mapped 
brain areas and their associated neurotransmitter signaling. It needs 
to be emphasized that the construction of brain-level networks 
depends heavily on proper labeling of brain areas. The task of brain 
parcellation is challenging, and can heavily infl uence the properties 
of obtained networks [ 147 ]. Table  3  summarizes  components and 
interactions of brain networks.
 The goal of a disease-oriented network approach on the brain level 
is primarily to synthesize experimental readouts from neuroimag-
ing studies into a coherent picture of changes in brain function and 
structure caused by specifi c pathogenesis [ 148 ]. Because brain net-
works are inferred directly from neuroimaging readouts, or from 
established brain topology, they are usually more homogeneous 
4.2  Disease-Specifi c 
Brain Networks
 Fig. 3  Brain-level networks represent  connections  between anatomical and functional brain areas, represent-
ing structural connections of directly interacting groups of neuronal cells, or functional associations between 
areas co-activated during a given type of brain activity 
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than molecular or cellular networks. Moreover, the neuroimaging 
 framework is similar for all neurological diseases, and network con-
struction efforts aim to identify brain areas associated with specifi c 
pathogeneses. Thus, in contrary to molecular networks, mecha-
nisms specifi c for different diseases will not affect the focus of the 
network being constructed. 
 One of the most widely used methods to construct disease-relevant 
brain networks is functional MRI (magnetic resonance imaging) , 
recording BOLD (blood-oxygen-level dependent) contrast signal 
in the brain during rest or while performing various tasks. Analysis 
of an  fMRI  signal allows to identify activated candidate areas, but 
is a nontrivial task, often requiring advanced data exploratory tech-
niques [ 149 ]. Identifi ed activated areas become elements in a 
brain-level network, while interactions are established on the basis 
of correlation of their co-activation [ 150 ,  151 ]. The approaches 
based on fMRI are numerous in the fi eld of neurological research. 
In the context of this review it is important to highlight research, 
where a systems approach is followed to obtain a global picture of 
the disease. An important example is the work of Baggio et al. 
[ 152 ], who analyzed resting-state fMRI data from PD, mild cogni-
tive impairment, and healthy subjects to reconstruct a global brain 
network associated with cognitive defi cits in PD. Another interest-
ing example of an fMRI study is the construction of a brain 
network for epilepsy by Toussaint and colleagues [ 153 ], aiming to 
highlight disruption in the functional network of the brain follow-
ing epileptic discharges. Network approaches to epilepsies are 
reviewed in [ 154 ]. 
 Another approach to identify and connect brain networks  is 
 neuroimaging of radiolabeled tracers. This approach highlights 
specifi c metabolic processes in the brain, involving the chosen 
radiotracer. The processes can be general, like glucose metabolism, 
or disease specifi c, like circulation of synaptic vesicles. The so-called 
metabolic networks of the brain are acquired in a similar manner to 
fMRI-derived networks, namely by analyzing temporal 
4.3  Construction 
of Brain-Level 
Networks
4.3.1  Identifi cation 
and Connecting 
of Candidate Areas
 Table 3 
 Elements and  interactions typically used for constructing brain-level networks 
 Interaction types 
 Element types 
 Structural 
connectivity 
 Functional 
association 
 Mapped 
connectivity 
 Functional area of metabolic activity  •  •  • 
 Functional area of neuronal activity  •  • 
 Anatomical area  •  • 
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correlations of radiotracer expression between different brain areas 
[ 155 ]. Such metabolic networks were recently constructed for PD 
[ 156 ] and AD [ 157 ]. 
 Structural brain networks represent physical connections 
between brain regions by white matter fi ber tracts. These connec-
tions are calculated on the basis of so-called  diffusion MRI 
(dMRI) measures  by  tractography approaches. Disease-associated 
alterations, either pathogenic or compensatory, may be refl ected in 
the topology of these structural connections [ 158 ]. Interestingly, 
these structural networks were recently shown to refl ect brain 
response to treatment of PD [ 159 ] and epilepsy [ 160 ]. 
 Finally, besides neuroimaging-based brain networks, prior knowl-
edge on brain anatomy and function is used to construct networks of 
disease-specifi c dysregulation of established brain circuits. One of 
such circuits is the default mode network, the brain circuit active 
when the brain performs no particular cognitive task. This network, 
for instance, was found distorted in AD [ 153 ,  161 ,  162 ] and in PD 
[ 152 ]. One of the very-well-explored disease- related circuits is the 
model of basal ganglia dysfunction in PD [ 163 ,  164 ]. The architec-
ture of corticobasal ganglia–cortical loops [ 165 ] is in fact a recon-
structed network, with interactions being projections of different 
neuronal subtypes to basal ganglia and cortical regions [ 166 ]. Here, 
 the  disturbance of these mapped circuits may be assessed using the 
technique of recording neuronal activity in local brain areas, called 
electroencephalography ( EEG) . EEG allows to obtain a good 
temporal resolution when measuring brain activity during epileptic 
seizures [ 167 ], or permits longitudinal tracking of the disruption of 
disease-relevant brain circuits, as shown for PD [ 168 ]. 
 Brain-level networks, whether neuroimaging based, or derived 
from prior knowledge, need to be evaluated concerning their rel-
evance and refi ned. One possible approach to reach this goal is 
correlation with available clinical data. In their study Morales and 
colleagues [ 169 ] performed a cognitive assessment of PD patients 
along with recording of the fMRI data and constructed non- 
overlapping subgroups of patients with different cognitive impair-
ments. This allowed them to improve the interpretation of 
neuroimaging data. Similarly to clinical assessment, drug therapy- 
related information can improve the quality of obtained networks. 
In a recent study, Cole and coworkers demonstrated that connec-
tivity among a number of well-defi ned brain circuits is infl uenced 
by dopamine therapy [ 170 ].  Finally , longitudinal neuroimaging 
can greatly help to refi ne and improve the quality of brain net-
works. This approach was considered by Seibyl et al. [ 171 ] to help 
stratifying subgroups of subjects and better approach the evolution 
of the disease. 
 Certain neurological disorders carry a signifi cant genetic bur-
den. This information can also be used to better tailor the 
4.3.2  Evaluation 
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constructed networks. In their work, Rao and colleagues per-
formed fMRI on HD patients taking into account the number of 
glutamine repeats in the huntingtin sequence. This stratifi cation, 
together with a list of HD-associated brain circuits, allowed them 
to identify networks specifi c to the forecasted severity of the disease 
[ 172 ]. Genetic stratifi cation was coupled  with  fMRI measurements 
of cognitive tasks in PD [ 173 ]. In this work Nombella and cowork-
ers demonstrated that three PD-associated alleles infl uence cogni-
tive systems in PD, although no direct network construction 
attempt was made. 
 Disease-specifi c brain-level networks are quite homogeneous con-
cerning their composition. Their common denominators are brain 
anatomy and function. Their construction usually heavily depends 
on supplementing neuroimaging data, where the most important 
factors are the choice of subjects and the neuroimaging approach. 
While dMRI supports construction of networks with fi xed topol-
ogy, fMRI and metabolic imaging can produce dynamic networks. 
Importantly, networks obtained with the latter approaches are cor-
relation based and represent patterns of temporal associations. 
Thus, their interpretation needs to be performed with care and 
prior information on mapped relevant brain circuits has to be taken 
into account. 
 Importantly, brain networks are the highest order representa-
tion of pathogenic processes in neurological diseases. This aggre-
gated view allows for convincingly linking the network disturbance 
to clinical endophenotypes. At the same time it is diffi cult to assess 
the emergence of the disturbance from the pathology on cellular 
and molecular levels. Here, improvements in metabolic imaging 
[ 156 ] and genetic stratifi cation of neuroimaging subjects [ 173 ] 
should allow to correlate molecular and brain-level networks. 
5  Synthesis 
 The brain is an extremely complex structure and this complexity 
can be observed on the level of the whole organ, cellular, and 
molecular organization. This nested network architecture,  illus-
trated  in Fig.  4 , increases the diffi culty in studying pathogenesis of 
neurological disorders. Nevertheless, systems approaches applied 
on each of these levels independently start to bring better under-
standing of the nature of these disorders.
 Regardless of the level of  brain  organization, construction of net-
works for the purpose of systems analysis involves a similar trade- 
off between the scope and the depth. Broad-scope networks, 
constructed on the basis of omics screens (molecular) [ 41 ], 
 micro- electrode arrays (cellular) [ 130 ], or MRI data (brain level) 
4.4  Summary
5.1  Cross-Scale 
Network Analysis
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[ 174 ,  175 ], have usually a broad scope, but limited depth. In effect, 
network- and systems-level analysis provides general large-scale 
insights into disruption of disease-associated brain function [ 33 ], 
microcircuits [ 138 ], and pathways [ 176 ]. On the other side, care-
fully constructed, focused networks offer detailed analyses and 
conclusions concerning the dynamics of the analyzed system. 
These focused networks require manual curation on the basis of 
known molecular interactions (molecular) [ 49 ], known or moni-
tored activity of cell populations (cellular) [ 177 ], or well-mapped 
brain circuits (whole brain) [ 178 ]. Currently, the size-scope trade- 
off is inevitable. However, as the efforts towards high-quality net-
work curation gain community-scale attention [ 47 ,  179 ], and new 
high-content screening approaches are proposed for network con-
struction [ 180 ], we may expect that disease-specifi c networks will 
grow in size without sacrifi cing their quality. 
 Concerning the  nested  network architecture, it is important 
not only to analyze in detail the behavior of a system on a given 
level of complexity—molecular, cellular, or whole brain—but also 
to cross the scales with the systems analysis. Experimental approaches 
allowing to achieve this cross-scale analysis are topic of intensive 
research. For instance, novel imaging techniques [ 181 ,  182 ] allow 
us to gain deep insights into the molecular basis of cellular dysfunc-
tion, as well as bridge between cellular and brain scales [ 139 ]. 
 What remains a challenge is a proper analytical approach to 
draw meaningful conclusions on the level of nested networks that 
will ultimately lead to better understanding of the disease. 
Currently, a number of computational approaches have been pro-
posed that bridge the cellular and brain-level networks, focusing 
on modeling neuronal activity from specifi c brain areas to gain 
insight into whole-brain network dynamics. The granularity of 
these approaches varies  from  simulation of spiking behavior of sin-
gle neuron [ 183 ] or neuronal population [ 184 ] models based on 
Hodgkin–Huxley equations to analysis of neurotransmitter release 
by specifi c brain circuits using reinforced learning models [ 185 ]. 
Axon
Nucleus
 Fig. 4  Networks  representing  brain disorder may be deeply nested, with each of the levels contributing to the 
phenotype 
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A framework bringing together molecular and higher scales still 
remains to be proposed; however efforts in this direction can be 
seen in brain  network reconstructions  concerning molecular profi les 
of subjects [ 172 ,  173 ]. 
6  Perspectives 
 Our current understanding of developmental processes, including 
brain development, encompasses the emergence of organ-level 
structure and function from elaborate cellular and molecular 
 interactions. We appreciate the importance of temporal and spatial 
dynamics of these processes, and associate their perturbations with 
pathogenic states. Similarly, when approaching diseases of an adult 
brain and analyzing associated pathological processes, we should 
consider molecular, cellular, and organ-level dysfunction simulta-
neously. Emerging evidence on close coupling between develop-
mental processes and the condition of specifi c neuronal 
subpopulations affected by neurodegeneration [ 186 ,  187 ] rein-
forces this perspective. 
 Systems biomedicine in  neurology is expected to gain insight 
into the complex nature of human brain and its disorders, facilitat-
ing accurate diagnosis, suggesting effi cient treatment, and, fi nally, 
allowing for preventing the pathogenesis. An important step to 
achieve these goals is to consider the brain as architecture of nested 
networks: molecular, cellular, and brain level. These networks 
become substrates of various mathematical and computational 
approaches, with an assumption that a given disorder is a dysfunc-
tion on a network level. Assembly of such a multi-layer network 
will require integration of data, but also of expertise. Community- 
driven approaches, like the Allen brain atlas [ 188 ] or the Parkinson’s 
disease map [ 47 ], extending well past the molecular layer, are 
needed to address this challenge. 
 Diseases with prominent molecular components, like prion 
diseases or HD, will primarily benefi t from detailed analysis of 
molecular networks. For these disorders to be pharmacologically 
treated, it is necessary to accurately identify mechanisms to target. 
Similarly, in the fi eld of chronic neurodegenerative diseases like PD 
or AD only symptomatic treatment is available. Consistent failure 
of drug design [ 189 ] and of gene-therapeutic approaches [ 190 ] 
reveals a pressing need for an insightful methodology to identify 
causal factors of these diseases, which should be likely sought on 
the molecular level. Importantly, concurrent or integrated analysis 
of cellular or brain level networks may allow to interpret how both 
molecular pathogenesis and drug treatment infl uence higher order 
brain networks [ 191 ]. 
 Disorders like epilepsies will primarily benefi t from insights 
from cellular and brain network analysis. Here, the pathogenic 
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state emerges in much shorter time frame than in chronic diseases. 
Distorted patterns of neuronal fi ring need to be stratifi ed for 
different epilepsy subtypes and analyzed for their response to treat-
ment [ 192 ]. Recent advances in multi-scale [ 193 ,  194 ]  and multi-
modal neuroimaging [ 195 ] come forward to meet the needs of an 
integrative network analysis approach. The assessment of treatment 
outcomes by cellular and brain network analysis is especially impor-
tant concerning increasing application of DBS in the fi eld of PD 
[ 196 ], but also epilepsies [ 197 ]. Currently, DBS electrodes deliver 
pacemaking stimulation in single site, and in an open loop. 
However, the possibility to read out the fi ring frequency of the 
neurons at the stimulation site allows designing feedback systems, 
or considering multi-site stimulation [ 198 ]. In both cases, systems 
analysis of cellular and brain networks is indispensable to properly 
design the therapeutic approaches. 
 Finally, advanced therapeutic and preventive approaches can 
benefi t from network analysis integrating molecular, cellular, and 
brain layers of complexity. One of them is regenerative medicine 
using stem cells [ 199 ,  200 ]. The main challenge in stem cell graft-
ing is the question where to place them. This, in turn, requires 
insights integrating information on molecular function of the cell, 
its role within the targeted tissue, and the impact of the grafted 
area on the whole-brain network structure and function. 
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